Publicado 05/09/2017 13:05CET
- Comunicado -

Real-world data confirms clinical effectiveness of Zebinix® (eslicarbazepine acetate) for the treatment of partial-onset

[2] World Health Organization. (2010) Epilepsy in The WHO European Region: Fostering Epilepsy Care in Europe. Cruquius, Paswerk Bedrijven. Available from: [ ] [Accessed August 2017].

[3] World Health Organization. (2017) Epilepsy Fact Sheet. Available from: [ ][Accessed August 2017].

[4] Eisai. (2017) Zebinix(R) (eslicarbazepine acetate) Summary of Product Characteristics. Available from: 88/WC500047225.pdf [ ]   [Accessed August 2017].

[5] Hebeisen S, et al. (2015) Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 89, 122-135

[6] Elger C, et al. (2007) Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 48, 497-504.

[7] Elger C, et al. (2009) Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial onset seizures: A randomised, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 50, 454-63.

[8] Ben-Menachem E, et al. (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Research. 89(2-3), 278-85.

[9] Gil-Nagel A, et al. (2009) Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurologica Scandinavica. 120, 281-87.

August 2017  Zebinix-EU0144  

CONTACT: Media Enquiries: Bial, Susana Vasconcelos,+35-1229-866-100/+35-1229-866-148,; Eisai,Helena Symeou, +44-7505-309-895,; Tonic LifeCommunications, Callum Haire, +44-7867-429-637,

Mejora la comunicación de tu empresa con Europa Press Comunicación